Tuesday, January 3, 2012
Peregrine Pharmaceuticals Inc., of Tustin, Calif., reported preliminary data analysis from its Phase II trial in hepatitis C virus indicating that the combination of phosphatidylserine-targeting antibody bavituximab and ribavirin appeared safe and well tolerated, with patients reporting fewer side effects than in the interferon-containing arm. Initial data also indicated that both dose levels of bavituximab (0.3 mg/kg or 3 mg/kg) with ribavirin demonstrated antiviral activity; however, the antiviral effects in patients receiving the 0.3 mg/kg dosing level were more pronounced.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.